do insurance companies cover glp-1 drugs MCT2D Important info! Most insurance companies
Description
A GLP-1 RA with proven cardiovascular benefit is recommended in patients with T2D who have albuminuric diabetic kidney disease (DKD) if a SGLT2 inhibitor is contraindicated or not tolerated
Bowker, N
Cardiovascular and kidney outcomes Tirzepatide has cardiovascular outcome data from the SURPASS-CVOT study, which showed favorable effects on major adverse cardiovascular events in people with type 2 diabetes
The effects are still meaningful, however
Like DMF, its a necessary component of solid-phase peptide synthesis, but its also volatile and environmentally unfriendly
